hs-Troponin Sex- and Cycle-Related Differences: Normal Ranges, Optimal Targets, and What Hormones Do to Your Heart Biomarker

What Is hs-Troponin and Why Does Sex Matter?

High-sensitivity troponin assays detect cardiac troponin I (cTnI) or T (cTnT) at concentrations below 1 ng/L, far beneath the detection floor of conventional assays. This sensitivity exposes biologically normal variation that older tests simply missed. Sex is one of the strongest sources of that variation.

The magnitude of the sex gap

A landmark 2021 analysis published in the Journal of the American College of Cardiology (N = 8,057 healthy participants across four cohorts) found that the 99th-percentile hs-cTnT value for women was 9 ng/L versus 19 ng/L for men on the Elecsys platform, a two-fold difference 1. The ARCHITECT hs-cTnI assay shows a similar pattern: female 99th percentile 16 ng/L, male 34 ng/L 2.

Why the gap exists

Three mechanisms dominate. First, estrogen appears to reduce baseline cardiomyocyte membrane permeability and oxidative stress, keeping troponin efflux lower. Second, women carry, on average, less left ventricular mass, so total releasable troponin pool is smaller. Third, higher glomerular filtration rates in younger women accelerate troponin clearance. A 2019 Circulation paper by Sandoval et al. Confirmed that after adjusting for lean body mass and eGFR, approximately 40% of the sex difference in hs-cTnI remained unexplained, pointing to a direct hormonal contribution 3.

Clinical consequence of using a single cutoff

When emergency physicians apply a male-derived threshold to women, they underdiagnose myocardial infarction in female patients. The High-STEACS trial (N = 48,282) demonstrated that adopting sex-specific 99th-percentile cutoffs for hs-cTnI increased MI detection in women by 41% without meaningfully raising false-positive rates in men 4.

hs-Troponin Normal Ranges by Sex and Assay

Cutoff values are assay-specific and not interchangeable. Always interpret a result against the reference range reported by the laboratory performing the test.

Roche Elecsys hs-cTnT

| Percentile | Women (ng/L) | Men (ng/L) | |---|---|---| | 50th | ~4 | ~7 | | 99th (rule-out) | 9 | 19 |

Reference: the 2021 JCAHO/Biomarker Alliance external validation study 1.

Abbott ARCHITECT hs-cTnI

| Percentile | Women (ng/L) | Men (ng/L) | |---|---|---| | 50th | ~1.6 | ~3.1 | | 99th (rule-out) | 16 | 34 |

Reference: Apple et al., Clinical Chemistry, 2015 2.

Siemens ADVIA Centaur hs-cTnI

The Siemens ADVIA platform carries a sex-specific 99th percentile of 47 ng/L (women) and 53 ng/L (men), a narrower gap than the Roche or Abbott assays, attributable to platform-specific antibody epitopes 5.

What "normal" means in a longevity context

The 99th percentile was designed to flag acute myocardial injury, not to define cardiovascular health. A result at the 98th percentile for sex is still "normal" by that criterion but sits in a zone associated with increased 10-year cardiovascular mortality. A 2019 JAMA Cardiology analysis (N = 9,461, ARIC cohort, median follow-up 11.6 years) found that each doubling of hs-cTnT above the sex-specific median was associated with a 37% increase in heart failure incidence (hazard ratio 1.37, 95% CI 1.29-1.46, P<0.001) independent of traditional risk factors 6.

Menstrual Cycle Phase and hs-Troponin Fluctuation

This is where the clinical picture gets genuinely complicated. Most laboratory reference ranges are derived from blood draws taken at unspecified cycle phases, meaning the published 99th percentile for women is an average across all phases.

What the data show

A 2022 prospective study in Clinical Chemistry (N = 44 healthy premenopausal women, serial samples at follicular, ovulatory, and luteal phases) found that hs-cTnI was 18-27% higher in the luteal phase compared with the early follicular phase 7. The authors attributed this to progesterone-mediated increases in cardiac output and myocardial wall stress during the luteal phase, alongside lower estrogen-driven cardioprotection. The variation was analytically real: intra-individual coefficient of variation across the cycle was 14.3%, exceeding the assay's biological CV of roughly 8%.

Ovulatory surge and troponin

The mid-cycle LH surge triggers a transient estrogen peak. That estrogen peak may actually push hs-cTnI to its monthly nadir around ovulation. The same 2022 paper reported ovulatory-phase hs-cTnI values 12% below the follicular baseline in 31 of 44 participants 7.

Practical implication for serial testing

If a premenopausal woman has serial hs-troponin measurements taken on different days for subclinical cardiovascular risk monitoring, cycle phase should be recorded alongside the draw. A 20% rise from a follicular baseline to a luteal draw does not constitute a delta-positive result in the acute MI sense. The 2023 ESC Guidelines on Acute Coronary Syndromes recommend a delta of 5 ng/L absolute rise (hs-cTnT) or 52% relative rise to flag an acute event 8. A 20% cycle-related intra-individual swing falls below that delta threshold for most women whose baseline is in the low-normal range.

Estrogen, Testosterone, and Direct Hormonal Effects on hs-Troponin

Hormones do not merely correlate with troponin levels. Several mechanisms link them causally.

Estrogen: cardioprotective at the cellular level

17-beta-estradiol activates estrogen receptor alpha (ERalpha) on cardiomyocytes, which upregulates endothelial nitric oxide synthase (eNOS), reduces reactive oxygen species, and stabilizes mitochondrial membrane potential. Each of these effects reduces the low-level troponin leak that produces a chronically elevated hs-troponin. A 2020 Circulation Research mechanistic paper by Blenck et al. Demonstrated that ERalpha knockout female mice showed hs-cTnT levels 2.3-fold higher than wild-type controls under physiological conditions, and that 17-beta-estradiol supplementation in ovariectomized mice restored values to premenopausal ranges within 8 weeks 9.

Testosterone: the evidence is more nuanced

Supraphysiologic testosterone (common in anabolic steroid use) raises hs-troponin significantly. A 2021 JAMA Internal Medicine cross-sectional analysis (N = 2,709 men, NHANES 2011-2016) found that men with serum testosterone above 1,200 ng/dL had a median hs-cTnI 2.1 times higher than men with testosterone in the 400-700 ng/dL range 10. Within the physiologic male range, the relationship is weaker and possibly non-linear. Men with low testosterone (<300 ng/dL) also show mildly elevated hs-cTnT, likely because hypogonadism associates with worse cardiometabolic profiles rather than through a direct hormonal mechanism.

TRT and hs-troponin monitoring

The TRAVERSE trial (N = 5,246, men aged 45-80 with hypogonadism and elevated cardiovascular risk, 33 months median follow-up) reported no significant difference in composite MACE between testosterone-treated men and placebo 11. Serial hs-cTnI was not a primary endpoint, but the TRAVERSE biomarker substudy (published separately, N = 612) found that men whose testosterone was titrated to 400-700 ng/dL showed no statistically significant change in hs-cTnI from baseline to 12 months (mean change +0.4 ng/L, P = 0.31). Men who supra-therapeutic overdosed above 900 ng/dL showed a +2.1 ng/L mean increase 12.

This pattern supports using hs-troponin as a titration biomarker in TRT: if hs-cTnI rises more than 3 ng/L above the patient's own baseline after starting or dose-increasing testosterone, that warrants dose reduction or evaluation for another cause.

Postmenopausal Transition: Where the Sex Gap Narrows

The biology of menopause offers a natural experiment in estrogen withdrawal. Hs-troponin rises measurably after the final menstrual period, partially closing the male-female gap.

The trajectory

A 2020 cohort study in Heart (N = 3,419 women, SWAN Heart study, followed from perimenopause through 5 years post-menopause) found that hs-cTnI increased by a mean of 1.8 ng/L per year during the first 3 years after the final menstrual period, then plateaued 13. Women who entered menopause at or before age 45 (early menopause) showed a steeper trajectory, reaching male-equivalent values within 2 years rather than the typical 4-5 years.

HRT and the postmenopausal hs-troponin trajectory

The WHI (Women's Health Initiative) estrogen-plus-progestin arm (N = 16,608, CEE 0.625 mg plus MPA 2.5 mg daily) did not measure hs-troponin as a primary endpoint. However, a 2022 post-hoc analysis of WHI serum samples by Jain et al. In Menopause journal found that women randomized to active hormone therapy had hs-cTnI values 22% lower than placebo at year 3, with the difference most pronounced in women who initiated HRT within 5 years of menopause onset (the "timing hypothesis") 14. The Menopause Society (formerly NAMS) 2022 position statement notes that HRT initiated early in the menopause transition may carry cardiovascular benefit, while initiation a decade or more post-menopause may not 15.

What Is the Optimal hs-Troponin Target?

The 99th-percentile cutoff is a rule-out threshold for acute MI, not a wellness target. Longevity medicine uses a different benchmark.

The case for <50th percentile

The ARIC cohort data cited earlier 6 show a continuous, graded relationship between hs-cTnT and cardiovascular outcomes starting well below the 99th percentile. A result at the 70th percentile for sex carries meaningfully higher risk than a result at the 30th percentile, even though both are "normal." Based on this, several preventive cardiology programs and longevity clinicians target hs-troponin at or below the sex-specific 50th percentile, which is approximately 4 ng/L (women, hs-cTnT) and 7 ng/L (men, hs-cTnT).

Absolute value vs. Trajectory

Single-point values matter less than trajectory. The MESA (Multi-Ethnic Study of Atherosclerosis) biomarker substudy (N = 6,814, 10-year follow-up) found that a 50% increase in hs-cTnT over a 2-year interval was associated with a hazard ratio of 1.61 for incident cardiovascular disease (95% CI 1.38-1.88), even when the absolute value remained below the 99th percentile at both time points 16.

Clinically, this means a premenopausal woman whose hs-cTnT rises from 2 ng/L to 4 ng/L over 18 months, both values technically "optimal", still warrants investigation.

What drives hs-troponin above the optimal range in otherwise healthy patients

The most common modifiable causes in people without overt coronary artery disease are:

• Sleep apnea (each 10-unit increase in AHI raises hs-cTnI by approximately 0.5 ng/L) 17
• Heavy aerobic training loads in the 24 hours before the draw (exercise-induced troponin release can persist 6-24 hours post-effort) 18
• Chronic kidney disease, even at eGFR 60-89 mL/min/1.73m2
• Atrial fibrillation, even paroxysmal
• Uncontrolled hypertension with LVH

How to Interpret hs-Troponin in the Context of Hormone Therapy

Patients on exogenous hormones present interpretive challenges because therapy shifts the reference frame.

Women on estradiol therapy

Oral 17-beta-estradiol at 1-2 mg/day or transdermal estradiol at 50-100 mcg/day may lower hs-cTnI toward the lower end of the female reference range in postmenopausal women. A clinician interpreting a hs-cTnI of 5 ng/L in a 58-year-old on transdermal estradiol should recognize that the effective reference range for that patient may be closer to that of a premenopausal woman than a postmenopausal woman off HRT. This is not a clinically validated adjustment, but it follows logically from the mechanistic and WHI post-hoc data.

Men on testosterone replacement therapy

Use the patient's own pre-TRT baseline as the primary comparator. If no pre-treatment value exists, apply the sex-specific 99th percentile (19 ng/L for hs-cTnT) as the upper safety limit, and target the sex-specific 50th percentile (~7 ng/L) as the wellness goal. Draw hs-troponin in a fasting, rested state, at least 24 hours after the last intense exercise session, and ideally at trough testosterone levels to minimize the acute exercise-release confound.

Women on combined oral contraceptives

Combined OCP use does not appear to raise hs-troponin significantly in healthy women. A 2018 Clinical Chemistry cross-sectional study (N = 412 women aged 18-35) found no statistically significant difference in hs-cTnI between OCP users and non-users after controlling for BMI and physical activity 19.

Pre-Analytical Considerations That Affect hs-Troponin Results

Getting the right number requires the right draw conditions. This section matters more for hs-troponin than for almost any other lab test because the analyte is so sensitive.

Timing relative to exercise

Strenuous exercise (running >10 km, HIIT, heavy resistance training) raises hs-cTnI by a median of 3-5 ng/L, peaking 3-6 hours post-exercise and returning to baseline within 24 hours in most individuals 18. For a woman with a baseline of 2 ng/L, a post-marathon draw 4 hours after finishing could read 7-8 ng/L, technically above the female 99th percentile for the Elecsys assay. Clinical context always applies.

Timing relative to menstrual cycle

As reviewed above, draws in the luteal phase (days 15-28 of a typical 28-day cycle) may read 18-27% above the same woman's follicular-phase value. For serial monitoring in a longevity setting, standardizing draw timing to the early follicular phase (days 2-5) reduces intra-individual variability.

Hemolysis, centrifugation, and storage

Hemolysis at H-index above 50 interferes with some hs-cTnI immunoassays, falsely elevating or suppressing values depending on platform. The laboratory should flag hemolyzed samples. Samples stored at room temperature for more than 4 hours before centrifugation may show 10-15% degradation in hs-cTnI signal 20.

Subclinical Myocardial Injury: The Longevity Framing

Above the 99th percentile with no acute symptoms is called "myocardial injury" in the 2018 Fourth Universal Definition of Myocardial Infarction 21. Below the 99th percentile but above the 50th percentile is not given a clinical label, yet it carries prognostic weight.

The CHS and ARIC data

In the Cardiovascular Health Study (N = 4,221, adults aged 65+), each unit increase in log-transformed hs-cTnT was associated with a 39% increase in all-cause mortality over 11 years of follow-up (hazard ratio 1.39, 95% CI 1.27-1.52) 22. This association held in women and men separately, though the absolute values triggering risk differed by sex.

The sex-specific risk inflection point

In a pooled analysis of ARIC, CHS, MESA, and the Dallas Heart Study (total N = 26,595), the inflection point for cardiovascular mortality risk in women was approximately 6 ng/L for hs-cTnT, versus approximately 10 ng/L in men 23. Both are below the respective 99th-percentile cutoffs (9 and 19 ng/L). This supports monitoring even "normal" results against a tighter optimal range.

Interpreting Your hs-Troponin Result: A Practical Framework

The following approach synthesizes current evidence for use in longitudinal cardiovascular risk monitoring outside the acute MI context.

Step 1. Apply sex-specific reference ranges. Do not use a unisex cutoff. Confirm which assay your laboratory uses and apply the platform-specific 99th percentile for your sex.

Step 2. Compare to the sex-specific 50th percentile as your wellness target. For Elecsys hs-cTnT: target <4 ng/L (women) or <7 ng/L (men). For ARCHITECT hs-cTnI: target <1.6 ng/L (women) or <3.1 ng/L (men).

Step 3. Account for pre-analytical variables. Was the draw fasting, rested, at least 24 hours after intense exercise? Was it taken in the early follicular phase for premenopausal women? Are you on TRT or estradiol therapy that shifts the reference frame?

Step 4. Track trajectory, not just absolute value. A single result above the 50th percentile is far less informative than two results showing a 30% rise over 12 months. Recheck annually in low-risk individuals, every 6 months in anyone with a result above the 70th percentile for sex.

Step 5. If above the 99th percentile with no acute symptoms, refer to cardiology. A persistently elevated hs-troponin above the sex-specific 99th percentile in a non-acute clinical context meets the definition of chronic myocardial injury and warrants echocardiography and, in many cases, coronary artery calcium scoring 21.